[1] Chan SL, Mo F, Johnson PJ, et al. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB(Oxford), 2014,16(4):366-372.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021,71(3):209-249.
[3] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis, 2017,65:15-21.
[4] 原发性肝癌诊疗规范(2019年版). 中国临床医学, 2020,27(01):140-160.
[5] Toyoda H, Kumada T, Tada T, et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci, 2011,102(5):1025-1031.
[6] Zhang Z, Zhang Y, Wang Y, et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther, 2015,9:123-129.
[7] Kumada T, Toyoda H, Tada T, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol, 2014,49(3):555-563.
[8] Chen H, Zhang Y, Li S, et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res,2018,10:1947-1958.
[9] Hu B, Tian X, Sun J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci, 2013,14(12):23559-23580.
[10] Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.Medicine(Baltimore), 2017,96(11):e5811.
[11] Wang X, Zhang W, Liu Y, et al. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer, 2017,12(1):47.
[12] Ji J, Wang H, Li Y, et al. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS ONE, 2016,11(4):e153227.
[13] Liu Z, Wu M, Lin D, et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res, 2020,48(2):1410560401.
[14] Xu F, Zhang L, He W, et al. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers, 2021,2021:8868370-8868379.
[15] Feng H, Li B, Li Z, et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer, 2021,21(1):401.
[16] 卫荣荣, 王成成, 李大江, 等. 异常凝血酶原对乙型肝炎病毒相关性AFP阴性肝癌的诊断价值研究. 四川大学学报(医学版), 2020,51(03):411-415.
[17] Anborgh PH, Mutrie JC, Tuck AB, et al. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med, 2010,14(8):2037-2044.
[18] Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012,55(2):483-490.
[19] Zhu M, Zheng J, Wu F, et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol, 2020,92(12):3596-3603.
[20] Ge T, Shen Q, Wang N, et al. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol, 2015,32(3):59.
[21] El-Khazragy N, Khalifa MM, Salem AM, et al. Evaluation of Osteopontin and Pokemon genes expression in hepatitis C virus-associated hepatocellular carcinoma. J Cell Biochem, 2018,120(5):7439-7445.
[22] Cheng J, Wang W, Sun C, et al. Meta-Analysis of the Prognostic and Diagnostic Significance of Serum/Plasma Osteopontin in Hepatocellular Carcinoma. J Clin Gastroenterol, 2014,48(9):806-814.
[23] Xiong Y, Xie CR, Zhang S, et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res, 2019,11:5745-5756.
[24] Wang T, Zhang KH, Hu PP, et al. Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget, 2016,7(39):64053-64070.
[25] Wang T, Zhang KH, Hu PP, et al. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. Oncotarget, 2017,8(58):97758-97768.
[26] She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol, 2015,47(2):543-554.
[27] Ma LN, Liu XY, Lu ZH, et al. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol Lett, 2017,13(5):3457-3464.
[28] Suner A, Carr BI, Akkiz H, et al. C-Reactive protein and platelet-lymphocyte ratio as potential tumor markers in low-alpha-fetoprotein hepatocellular carcinoma. Oncology, 2019,96(1):25-32.
[29] Jing W, Peng R, Zhu M, et al. Differential expression and diagnostic significance of pre-albumin, fibrinogen combined with D-Dimer in AFP-Negative hepatocellular carcinoma. Pathol Oncol Res, 2020,26(3):1669-1676.
[30] Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci, 2019,15(1):221-228.
[31] Huang L, Mo Z, Hu Z, et al. Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma. Cancer Cell Int, 2020,20(1):77.
[32] Li J, Tao H, Zhang E, et al. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma. Cancer Med, 2021,10(14):4844-4854.
[33] Luo CL, Rong Y, Chen H, et al. A logistic regression model for noninvasive prediction of afp-negative hepatocellular carcinoma. Technol Cancer Res Treat, 2019,18:1078114280.
[34] Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016,54(12):1296-1305.
[35] Zhang X, Wang T, Zhang KH, et al. Simple clinical metrics enhance afp to effectively identify cirrhotic patients with complicating hepatocellular carcinoma at various AFP levels. Front Oncol, 2019,9:1478.
[36] Zhu L, Li T, Ma X, et al. A simple noninvasive index can predict hepatocellular carcinoma in patients with chronic hepatitis B. Sci Rep, 2017,7(1):8910-8954. |
